Country: United States
Language: English
Source: NLM (National Library of Medicine)
SELEGILINE HYDROCHLORIDE (UNII: 6W731X367Q) (SELEGILINE - UNII:2K1V7GP655)
i3 Pharmaceuticals, LLC
ORAL
PRESCRIPTION DRUG
Selegiline Hydrochloride Tablets, USP are indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking
Selegiline Hydrochloride Tablets, USP 5 mg are available for oral administration as white, unscored, round tablets debossed with “i3” on one side and “6” on the other side. They are supplied as bottle of 60 (NDC 72319-006-02). Store at 20° to 25°C (68° to 77°F); excursions 15˚ to 30˚C (59˚ to 86˚F). [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container [see USP] with a child-resistant closure as required. i3 Pharmaceuticals, LLC SELEGILINE HYDROCHLORIDE TABLETS, USP 5 mg Manufactured by: i3 Pharmaceuticals, LLC 200 Park Ave Warminster, PA 18974 OS006-02 REV.1220 Revised: December 2020
Abbreviated New Drug Application
SELEGILINE HYDROCHLORIDE- SELEGILINE HYDROCHLORIDE TABLET I3 PHARMACEUTICALS, LLC ---------- SELEGILINE HYDROCHLORIDE TABLETS, USP 5 MG DESCRIPTION Selegiline hydrochloride is a levorotatory acetylenic derivative of phenethylamine. It is commonly referred to in the clinical and pharmacological literature as 1-deprenyl. The chemical name is: (R)-(-)- _N_,2-dimethyl- _N_-2-propynylphenethylamine hydrochloride. It is a white to near white crystalline powder, freely soluble in water, chloroform, and methanol, and has a molecular weight of 223.74. The molecular formula is C H N•HCl. The structural formula is as follows: Each tablet, for oral administration, contains 5 mg selegiline hydrochloride. Inactive ingredients are corn starch, lactose monohydrate, microcrystalline cellulose, povidone, and stearic acid. CLINICAL PHARMACOLOGY The mechanisms accounting for selegiline’s beneficial adjunctive action in the treatment of Parkinson’s disease are not fully understood. Inhibition of monoamine oxidase, type B, activity is generally considered to be of primary importance; in addition, there is evidence that selegiline may act through other mechanisms to increase dopaminergic activity. Selegiline is best known as an irreversible inhibitor of monoamine oxidase (MAO), an intracellular enzyme associated with the outer membrane of mitochondria. Selegiline inhibits MAO by acting as a ‘suicide’ substrate for the enzyme; that is, it is converted by MAO to an active moiety which combines irreversibly with the active site and/or the enzyme’s essential FAD cofactor. Because selegiline has greater affinity for type B rather than for type A active sites, it can serve as a selective inhibitor of MAO type B if it is administered at the recommended dose. MAOs are widely distributed throughout the body; their concentration is especially high in liver, kidney, stomach, intestinal wall, and brain. MAOs are currently subclassified into two types, A and B, which differ in their substrate specificity and tissue distribution. In huma Read the complete document